We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.87%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$431M
AUM Growth
+$70.9M
Cap. Flow
+$79.1M
Cap. Flow %
18.34%
Top 10 Hldgs %
23.13%
Holding
178
New
54
Increased
29
Reduced
23
Closed
43

Top Buys

Rank Stock Value
1
XTNT icon
Xtant Medical Holdings
XTNT
+$14.7M
2
PALI icon
Palisade Bio
PALI
+$11M
3
POL.WS
Polished.com Inc. Warrants to Purchase Common Stock
POL.WS
+$10.1M
4
ECOR icon
electroCore
ECOR
+$8.6M
5
KLR
Kaleyra, Inc.
KLR
+$8.24M

Top Sells

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$8.32M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.67M
3
STRO icon
Sutro Biopharma
STRO
+$5.16M
4
MBTCU
Nocturne Acquisition Corporation Unit
MBTCU
+$5M
5
IMNN icon
Imunon
IMNN
+$4.83M

Sector Composition

Rank Sector Weight
1 Healthcare 84.75%
2 Financials 3.74%
3 Technology 1.96%
4 Consumer Discretionary 0.54%
5 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTXW
126
DELISTED
Immatics N.V. Warrants
IMTXW
$335K 0.08%
97,467
– –
IKT icon
127
Inhibikase Therapeutics
IKT
$380M
$307K 0.07%
+18,292
New +$538K
RCAT icon
128
Red Cat Holdings
RCAT
$1.34B
$266K 0.06%
+102,290
New +$308K
MBTCR
129
DELISTED
Nocturne Acquisition Corporation Right
MBTCR
$190K 0.04%
+500,000
New +$194K
EUCRW
130
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$139K 0.03%
+133,333
New +$120K
SNCR
131
DELISTED
Synchronoss Technologies
SNCR
$117K 0.03%
+3,611
New +$102K
OBIO icon
132
Orchestra BioMed
OBIO
$249M
$102K 0.02%
10,000
– –
SRXH
133
SRX Global
SRXH
$27.1M
$86K 0.02%
+10
New +$82.2K
TMPMW
134
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$78K 0.02%
+84,666
New +$71.7K
UPH.WS
135
DELISTED
UpHealth, Inc. Warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share
UPH.WS
$9K ﹤0.01%
+10,000
New +$10.2K
BWAY
136
Brainsway
BWAY
$627M
– –
-359,012
Closed -$1.62M
CHRS icon
137
Coherus Oncology
CHRS
$180M
– –
-136,623
Closed -$2M
DNTH icon
138
Dianthus Therapeutics
DNTH
$6B
– –
-10,274
Closed -$1.95M
EVAX
139
Evaxion A/S
EVAX
$25M
– –
-495
Closed -$146K
FBRX icon
140
Forte Biosciences
FBRX
$1.57B
– –
-5,382
Closed -$4.61M
GNPX icon
141
Genprex
GNPX
$2.27M
– –
-1
Closed -$263K
GYRE icon
142
Gyre Therapeutics
GYRE
$710M
– –
-11,991
Closed -$453K
HLMN icon
143
Hillman Solutions
HLMN
$1.77B
– –
-192,314
Closed -$1.93M
IMNN icon
144
Imunon
IMNN
$6.68M
– –
-17,869
Closed -$4.83M
IRON icon
145
Disc Medicine
IRON
$3B
– –
-6,800
Closed -$2.76M
JSPRW icon
146
Japer Therapeutics Warrants
JSPRW
$180K
– –
-162,500
Closed -$133K
LRMR icon
147
Larimar Therapeutics
LRMR
$438M
– –
-93,261
Closed -$1.36M
NAUT icon
148
Nautilus Biotechnolgy
NAUT
$112M
– –
-286,383
Closed -$3.95M
PXS icon
149
Pyxis Tankers
PXS
$49.4M
– –
-508,948
Closed -$2.1M
DCOY
150
Decoy Therapeutics
DCOY
$2.26M
– –
-35
Closed -$1.85M
4 5
6
7 8

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return

Altium Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Altium Capital Management held 178 positions worth $431M, up 20% from $360M the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Altium Capital Management deployed $79.1M of net new capital in Q2 2021, opening 54 new positions and adding to 29 existing holdings. Its largest new stake was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 83% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Verastem, an estimated $2.98M trimmed.

  • Altium Capital Management's largest Q2 2021 buy was Xtant Medical Holdings: 8,292,602 shares worth $13.5M.
  • Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q2 2021, an estimated $7.41M increase.
  • Altium Capital Management's biggest Q2 2021 reduction was Verastem, cutting an estimated $2.98M.
  • Altium Capital Management fully exited Biora Therapeutics, Inc. Common Stock in Q2 2021, selling an estimated $8.32M.
  • Altium Capital Management's ten largest holdings make up 23% of its $431M portfolio in Q2 2021.
  • Altium Capital Management opened 54 new positions and closed 43 in Q2 2021.
  • Altium Capital Management's portfolio value rose 20% quarter-over-quarter to $431M.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.